Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy
Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy
Status: Enrolling
Updated:  8/4/2015
Behavioral Sleep Medicine Program, Department of Psychiatry, University of Pennsylvania
mi
from
Philadelphia, PA
Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy
Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy
Status: Enrolling
Updated: 8/4/2015
Behavioral Sleep Medicine Program, Department of Psychiatry, University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer
A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer
Status: Enrolling
Updated:  8/4/2015
Southern Illinois University School of Medicine
mi
from
Springfield, IL
A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer
A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer
Status: Enrolling
Updated: 8/4/2015
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Click here to add this to my saved trials
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Status: Enrolling
Updated:  8/4/2015
Ingalls Memorial Hospital
mi
from
Harvey, IL
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Status: Enrolling
Updated: 8/4/2015
Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Status: Enrolling
Updated:  8/4/2015
NCI
mi
from
Rockville, MD
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Status: Enrolling
Updated: 8/4/2015
NCI
mi
from
Rockville, MD
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Huntsville, AL
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Mobile, AL
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Fayetteville, AR
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Fayetteville, AR
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Bakersfield, CA
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Bakersfield, CA
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Fountain Valley, CA
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Greenbrae, CA
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Greenbrae, CA
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Los Angeles, CA
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Pleasant Hill, CA
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Pleasant Hill, CA
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Fairfield, CT
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Fairfield, CT
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Stamford, CT
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Stamford, CT
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Washington,
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Gainesville, FL
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Gainesville, FL
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Orlando, FL
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Tamarac, FL
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Tamarac, FL
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Atlanta, GA
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Augusta, GA
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Lawrenceville, GA
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Lawrenceville, GA
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Niles, IL
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Niles, IL
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Iowa City, IA
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Waterloo, IA
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Waterloo, IA
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Baltimore, MD
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Rockville, MD
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Rockville, MD
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
mi
from
Brownstown, MI
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
mi
from
Brownstown, MI
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Kalamazoo, MI
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Southfield, MI
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Southfield, MI
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Kansas City, MO
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
St Louis, MO
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
St Louis, MO
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Long Branch, NJ
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Long Branch, NJ
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Bronx, NY
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Hickory, NC
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Winston-Salem, NC
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Cincinnati, OH
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Columbus, OH
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Middletown, OH
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Middletown, OH
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Columbia, SC
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Columbia, SC
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Chattanooga, TN
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Germantown, TN
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Germantown, TN
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Nashville, TN
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Austin, TX
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Dallas, TX
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
mi
from
Rutland, VT
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
mi
from
Rutland, VT
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Abingdon, VA
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Abingdon, VA
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
Clinical Research Facility
mi
from
Richmond, VA
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated:  8/5/2015
mi
from
Buenos Aires,
BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer
An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in "Triple Negative" Breast Cancer.
Status: Enrolling
Updated: 8/5/2015
mi
from
Buenos Aires,
Click here to add this to my saved trials
Acupressure for Persistent Cancer Related Fatigue
Acupressure for Persistent Cancer-Related Fatigue in Breast Cancer Survivors
Status: Enrolling
Updated:  8/5/2015
University of Michigan
mi
from
Ann Arbor, MI
Acupressure for Persistent Cancer Related Fatigue
Acupressure for Persistent Cancer-Related Fatigue in Breast Cancer Survivors
Status: Enrolling
Updated: 8/5/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of Excision Repair Cross Complementation Gene 1 (ERCC1) in Treatment Decision
Status: Enrolling
Updated:  8/5/2015
Emory University Hospital Midtown
mi
from
Atlanta, GA
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of Excision Repair Cross Complementation Gene 1 (ERCC1) in Treatment Decision
Status: Enrolling
Updated: 8/5/2015
Emory University Hospital Midtown
mi
from
Atlanta, GA
Click here to add this to my saved trials